Miro Venturi is one of LongeVC's Advisory Board members. He is an enthusiastic professional with extensive experience in the pharmaceutical sector.
In 2002, Miro joined the pharmaceutical industry as a Biomarker Laboratory Head and project team representative at Pharmacia Corp (later Pfizer Inc.) at the Oncology R&D site. In this role, he established the biomarker laboratories and actively contributed to developing numerous oncology programs focusing on small molecular weight kinase inhibitors. In 2005, Miro was invited to join the University "Vita Salute San Raffaele" faculty in Milan as an Adjunct Professor of preclinical and early clinical development of biopharmaceuticals. Later, in 2007, Miro moved to Novartis as its Divisional Head in Biomarker Development, supervising a team of scientists developing assays and supporting project teams to realise personalised medicine strategies across the portfolio.
Miro's team has contributed to the development of nilotinib (Tasigna) and early programs in solid tumours and haematological malignancies. In 2009, Miro joined Roche Oncology, where he contributed to the biomarker and personalised medicine strategies and directed the execution of global drug development programs with companion diagnostics. In 2011, he was appointed Site Head for Oncology Biomarkers within the DTA Oncology Department. Miro was then appointed Global Head of Diagnostics Biomarkers at Hoffmann-la Roche.
Miro has contributed to several drug research and scientific development projects and published in relevant scientific journals, including Nature, Cell, and PNAS. Currently, Miro is an Advisory Committee Member of Bios+ Bellinzona Institute of Sciences and a Board Member of Sintetica SA - Innovating Therapies
Miro holds a Master's degree in Biochemistry from Alma Mater Studiorum, Università di Bologna, and a PhD in Biochemistry - Molecular Biophysics from Goethe University. His Post Doctorate is in Vaccine Design - Structural Biology - Molecular Virology from the National Institutes of Health.